Department of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, People's Republic of China.
Jiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Drug Des Devel Ther. 2023 Sep 12;17:2805-2819. doi: 10.2147/DDDT.S417954. eCollection 2023.
This study aims to confirm the efficacy of Xijiao Dihuang decoction (XJDHT), a classic prescription, in treating psoriasis and to explore the potential therapeutic mechanism.
For pharmacodynamic analysis, a mouse model of imiquimod cream (IMQ)-induced psoriasis was constructed. Active ingredients and genes of XJDHT, as well as psoriasis-related targets, were obtained from public databases. Intersecting genes (IGEs) of XJDHT and psoriasis were collected by Venn Diagram. A protein-protein interaction (PPI) network of IGEs is constructed through the STRING database. The Molecular Complex Detection (MCODE) and Cytohubba plug-ins of Cytoscape software were used to identified hub genes. In addition, we conducted enrichment analysis of IGEs using the R package clusterProfiler. Hub genes were validated via external GEO databases. The influence of XJDHT on Hub gene expression was examined by qPCR and ELISA, and molecular docking was used to evaluate the binding efficacy between active ingredients and hub genes.
The results revealed that XJDHT possesses 92 potential genes for psoriasis, and 8 Hub genes were screened. Enrichment analysis suggested that XJDHT ameliorate psoriasis through multiple pathways, including AGE-RAGE, HIF-1, IL-17 and TNF signaling pathway. Validation data confirmed the differential expression of IL6, VEGFA, TNF, MMP9, STAT3, and TLR4. Molecular docking revealed a strong affinity between active ingredients and Hub genes. The efficacy of XJDHT in improving psoriatic lesions in model mice was demonstrated by PASI score and HE staining, potentially attributed to the down-regulation of VEGFA, MMP9, STAT3, TNF, and IL-17A, as evidenced by ELISA and qPCR.
This study employed network pharmacology and in vitro experiments to identify the potential mechanisms underlying the therapeutic effects of XJDHT on psoriasis, providing a new theoretical basis for its clinical application in the treatment of psoriasis.
本研究旨在验证经典方剂犀角地黄汤(XJDHT)治疗银屑病的疗效,并探讨其潜在的治疗机制。
采用咪喹莫特乳膏(IMQ)诱导的银屑病小鼠模型进行药效学分析。从公共数据库中获取 XJDHT 的活性成分和基因,以及银屑病相关靶点。通过 Venn 图收集 XJDHT 和银屑病的交集基因(IGE)。通过 STRING 数据库构建 IGE 的蛋白质-蛋白质相互作用(PPI)网络。使用 Cytoscape 软件的 Molecular Complex Detection(MCODE)和 Cytohubba 插件识别关键基因。此外,我们使用 R 包 clusterProfiler 对 IGE 进行富集分析。通过外部 GEO 数据库验证关键基因。通过 qPCR 和 ELISA 检测 XJDHT 对关键基因表达的影响,并进行分子对接评估活性成分与关键基因的结合效力。
结果表明,XJDHT 对银屑病具有 92 个潜在的作用基因,筛选出 8 个关键基因。富集分析表明,XJDHT 通过 AGE-RAGE、HIF-1、IL-17 和 TNF 信号通路等多种途径改善银屑病。验证数据证实了 IL6、VEGFA、TNF、MMP9、STAT3 和 TLR4 的差异表达。分子对接显示活性成分与关键基因之间具有很强的亲和力。XJDHT 通过降低 VEGFA、MMP9、STAT3、TNF 和 IL-17A 的表达,改善模型小鼠的银屑病病变,这可通过 ELISA 和 qPCR 得到证实。
本研究采用网络药理学和体外实验方法,鉴定了 XJDHT 治疗银屑病的潜在作用机制,为其在银屑病临床治疗中的应用提供了新的理论依据。